search
Back to results

A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression

Primary Purpose

Bipolar Depression

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
aripiprazole
Sponsored by
Lindner Center of HOPE
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Depression focused on measuring Adults, Bipolar Depression, Bipolar Disorder, Bipolar I, Bipolar II, Depression

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: subjects must have bipolar I, II or NOS disorder as defined by DSM-IV-TR; must have clinical significant depressive symptoms and have failed one or more mood stabilizer trials; may or may not be receiving antimanic or mood stabilizing medications; subjects or legally authorized representative must sign the Informed Consent document after the nature of the trial has been fully explained; if female, subjects must be postmenopausal, surgically incapable of childbearing or practicing medically acceptable effective method(s) of contraception. Exclusion Criteria: subjects who do not have bipolar disorder by DSM-IV criteria; subjects with current DSM-IV Axis I diagnosis of delirium, dementia, amnesia or other cognitive disorders or a psychotic disorder; subjects with serious general medical illness; subjects who are allergic to or have demonstrated hypersensitivity to aripiprazole; women who are pregnant or nursing; subjects who have received an experimental drug or used an experimental device within 30 days; subjects who have a history of neurologic malignant syndrome.

Sites / Locations

  • University of Cincinnati Medical Center

Outcomes

Primary Outcome Measures

Montgomery-Asberg Depression Rating Scale (MADRS)

Secondary Outcome Measures

Clinical Global Impression Scale Modified for Bipolar Illness (CGI-BP)

Full Information

First Posted
August 11, 2006
Last Updated
June 21, 2011
Sponsor
Lindner Center of HOPE
Collaborators
University of Cincinnati
search

1. Study Identification

Unique Protocol Identification Number
NCT00363337
Brief Title
A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression
Study Type
Interventional

2. Study Status

Record Verification Date
June 2011
Overall Recruitment Status
Completed
Study Start Date
August 2006 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
March 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Lindner Center of HOPE
Collaborators
University of Cincinnati

4. Oversight

5. Study Description

Brief Summary
The specific aim of this study is to obtain preliminary evidence of the acute effectiveness and tolerability of aripiprazole in the treatment of bipolar depression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Depression
Keywords
Adults, Bipolar Depression, Bipolar Disorder, Bipolar I, Bipolar II, Depression

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
aripiprazole
Other Intervention Name(s)
Abilify
Intervention Description
open label treatment with aripiprazole
Primary Outcome Measure Information:
Title
Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame
per protocol
Secondary Outcome Measure Information:
Title
Clinical Global Impression Scale Modified for Bipolar Illness (CGI-BP)
Time Frame
per protocol

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: subjects must have bipolar I, II or NOS disorder as defined by DSM-IV-TR; must have clinical significant depressive symptoms and have failed one or more mood stabilizer trials; may or may not be receiving antimanic or mood stabilizing medications; subjects or legally authorized representative must sign the Informed Consent document after the nature of the trial has been fully explained; if female, subjects must be postmenopausal, surgically incapable of childbearing or practicing medically acceptable effective method(s) of contraception. Exclusion Criteria: subjects who do not have bipolar disorder by DSM-IV criteria; subjects with current DSM-IV Axis I diagnosis of delirium, dementia, amnesia or other cognitive disorders or a psychotic disorder; subjects with serious general medical illness; subjects who are allergic to or have demonstrated hypersensitivity to aripiprazole; women who are pregnant or nursing; subjects who have received an experimental drug or used an experimental device within 30 days; subjects who have a history of neurologic malignant syndrome.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan L McElroy, MD
Organizational Affiliation
University of Cincinnati
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Cincinnati Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267-0559
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
17229469
Citation
McElroy SL, Suppes T, Frye MA, Altshuler LL, Stanford K, Martens B, Leverich GS, Post RM, Keck PE Jr. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord. 2007 Aug;101(1-3):275-81. doi: 10.1016/j.jad.2006.11.025. Epub 2007 Jan 16.
Results Reference
result

Learn more about this trial

A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression

We'll reach out to this number within 24 hrs